MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Open Access
- 16 November 2012
- journal article
- abstracts
- Published by American Society of Hematology in Blood
- Vol. 120 (21) , 727